Article date: May 2008
By: Osamah Hussein, LiLia Minasian, Yaroslav Itzkovich, Karina Shestatski, Lizora Solomon, Jamal Zidan, in Volume 65, Issue 5, pages 637-645
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
AIMS
To investigate the effect of lowering low‐density lipoprotein‐cholesterol (LDL‐C) on platelet aggregation and LDL tendency to peroxidation by ezetimibe alone or with simvastatin in hypercholesterolaemia.
METHODS
Sixteen patients with LDL‐C >3.4 mmol l−1 received ezetimibe for 3 months (Part I). Twenty‐two patients on fixed simvastatin dose with LDL‐C >2.6 mmol l−1 were enrolled (Part II). Part II patients continued simvastatin treatment 20 mg day−1 for 6 weeks, then received 20 mg day−1 simvastatin combined with ezetimibe 10 mg day−1 for another 6 weeks. The tendency of LDL to peroxidation measured by lag time in minutes required for initiation of LDL oxidation and by LDL oxidation at maximal point (plateau) was measured before and after ezetimibe treatment.
RESULTS
Part I: Ezetimibe 10 mg daily for 3 months decreased plasma LDL‐C level 16% (P = 0.002), prolonged lag time to LDL oxidation from 144 ± 18 min to 195 ± 16 min (P < 0.001), decreasing maximal aggregation from 83 ± 15% to 60 ± 36% (P = 0.04). Part II: Serum level LDL‐C decreased 23% (P = 0.02) and lag time in minutes to LDL oxidation was prolonged from 55.9 ± 16.5 to 82.7 ± 11.6 (P < 0.0001) using combined simvastatin–ezetimibe therapy. There were no differences in platelet aggregation.
CONCLUSIONS
Ezetimibe was associated with decreased platelet aggregation and LDL tendency to peroxidation. Treatment with ezetimibe in addition to simvastatin has an additive antioxidative effect on LDL.
DOI: 10.1111/j.1365-2125.2007.03080.x
View this article